Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Mar 1;46(3):245-247.
doi: 10.1097/MNM.0000000000001938. Epub 2024 Dec 6.

Safety observations in neuroblastoma patients undergoing 18 F- m FBG PET

Neeta Pandit-Taskar  1 , Ellen Basu  2 , Eloisa Balquin  1 , P David Mozley  3 , Arnold F Jacobson  3 , Shakeel Modak  2
Affiliations
Clinical Trial

Safety observations in neuroblastoma patients undergoing 18 F- m FBG PET

Neeta Pandit-Taskar et al. Nucl Med Commun. .

Abstract

Objective: Limited safety data have been published on fluorine-18 ( 18 F) meta-fluorobenzylguanidine ( m FBG), a new PET radiopharmaceutical for imaging neural crest and neuroendocrine tumors. As part of a prospective clinical trial, safety data in patients with neuroblastoma were collected and analyzed.

Methods: Between April 2015 and January 2022, 27 patients with neuroblastoma underwent 18 F- m FBG PET imaging as part of an ongoing single-center phase 1/2 trial (NCT02348749). Pre- and postinjection safety assessments were performed, including vital sign measurement and observation for occurrence of adverse events (AEs).

Results: m FBG administration resulted in no significant changes in measured vital signs. Two subjects had transient, grade 1 facial flushing shortly after the administration, which resolved within a few minutes. Neither subject had a clinically significant change in pulse or blood pressure on postadministration measurements.

Conclusion: In this investigation of the potential clinical utility of m FBG PET imaging, no significant adverse safety signals were noted. Two mild, self-limited AEs were observed, without associated changes in vital signs. No grade 2 or higher AEs were noted. The findings are consistent with a favorable safety profile for m FBG in the target population of patients with neuroblastoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Ellen Basu and Eloise Balquin have no conflicts to disclose.

References

    1. Maris J, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007. Jun 23;369(9579):2106–2120. - PubMed
    1. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2017; 35(22):2580–2587. - PMC - PubMed
    1. Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017. Mar;47(2):143–157 - PubMed
    1. Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TP. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer. 2015. Jan;62(1):5–11. - PMC - PubMed
    1. Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009; 52:784–790. - PubMed

Publication types

Substances